BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24727373)

  • 1. PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy.
    Rybalov M; Ananias HJ; Hoving HD; van der Poel HG; Rosati S; de Jong IJ
    Int J Mol Sci; 2014 Apr; 15(4):6046-61. PubMed ID: 24727373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
    Ananias HJ; van den Heuvel MC; Helfrich W; de Jong IJ
    Prostate; 2009 Jul; 69(10):1101-8. PubMed ID: 19343734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
    Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.
    Eder M; Schäfer M; Bauder-Wüst U; Haberkorn U; Eisenhut M; Kopka K
    Prostate; 2014 May; 74(6):659-68. PubMed ID: 24464532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific radioligands targeting prostate-specific membrane antigen and gastrin-releasing peptide receptors on the surface of prostate cancer cells.
    Liolios C; Sachpekidis C; Schäfer M; Kopka K
    J Labelled Comp Radiopharm; 2019 Jun; 62(8):510-522. PubMed ID: 31070273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will GRPR Compete with PSMA as a Target in Prostate Cancer?
    Iagaru A
    J Nucl Med; 2017 Dec; 58(12):1883-1884. PubMed ID: 28970333
    [No Abstract]   [Full Text] [Related]  

  • 8. Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors.
    Liolios C; Patsis C; Lambrinidis G; Tzortzini E; Roscher M; Bauder-Wüst U; Kolocouris A; Kopka K
    Mol Pharm; 2022 Jul; 19(7):2231-2247. PubMed ID: 35467350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.
    Santana SM; Liu H; Bander NH; Gleghorn JP; Kirby BJ
    Biomed Microdevices; 2012 Apr; 14(2):401-7. PubMed ID: 22143878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
    BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of peptide-based imaging agents [
    Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A
    Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
    Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
    Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro.
    Kraaij R; van Rijswijk AL; Oomen MH; Haisma HJ; Bangma CH
    Prostate; 2005 Feb; 62(3):253-9. PubMed ID: 15389777
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
    Maurer T; Gschwend JE; Eiber M
    Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.
    Wernicke AG; Varma S; Greenwood EA; Christos PJ; Chao KS; Liu H; Bander NH; Shin SJ
    APMIS; 2014 Jun; 122(6):482-9. PubMed ID: 24304465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice.
    Zhao LY; Mao XP; Chao KY; Guo SJ; Qiu SP
    Braz J Med Biol Res; 2012 Aug; 45(8):737-45. PubMed ID: 22584637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
    Benko G; Spajić B; Krušlin B; Tomas D
    Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific membrane antigen expression in melanoma metastases.
    Snow H; Hazell S; Francis N; Mohammed K; O'Neill S; Davies E; Mansfield D; Messiou C; Hujairi N; Nicol D; Harrington K; Smith M
    J Cutan Pathol; 2020 Dec; 47(12):1115-1122. PubMed ID: 32529651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.